 Emergent BioSolutions Inc NYSE: EBS reported Q1 sales of 307.5 million, down 10 YY, beating the consensus of 283 million. Total product sales increased 72 to 237.1 million, while Contract development manufacturing CDMO revenues declined 67 to 60.8 million. 